MARKET

PFE

PFE

Pfizer
NYSE
27.55
-0.10
-0.36%
Opening 11:14 06/14 EDT
OPEN
27.73
PREV CLOSE
27.65
HIGH
28.21
LOW
27.43
VOLUME
9.68M
TURNOVER
0
52 WEEK HIGH
40.37
52 WEEK LOW
24.83
MARKET CAP
156.11B
P/E (TTM)
-427.1318
1D
5D
1M
3M
1Y
5Y
CDC 'preparing for the possibility' bird flu could spread more easily
Healthcare CDC 'preparing for the possibility' bird flu could spread more easily. Only three human bird flu cases have been identified in the U.S. So far. The H5N1 avian flu circulating in animals still poses a low risk to humans.
Seeking Alpha · 17m ago
Structure Therapeutics: Yet Another Potential GLP-1 Entrant
Structure Therapeutics Inc. Shares surged over 50% on positive GSBR-1290 data, competing with other oral GLP-1R clinical rivals. The company used the spike in the stock to raise additional capital. Shares of Structure Therapeutic Inc. Rallied over 50%. Structure is developing a drug for the treatment of type II diabetes and obesity. Its efficacy at week 12 fell below Novo Nordisk's amycretin but still competitive in the obesity treatment landscape.
Seeking Alpha · 51m ago
Benjamin Graham Detailed Fundamental Analysis - PFE
NASDAQ · 2h ago
Pharma Stock Roundup: FDA Panel Endorses LLY's Donanemab, PFE's DMD Therapy Study Fails
NASDAQ · 2h ago
Pfizer's Elrexfio buoyed by multiple myeloma survival data
Multiple myeloma patients treated with Pfizer's Elrexfio demonstrated a median survival of 24.6 months in a phase 2 trial. The overall response rate for treated patients was 61.0% in the MagnetisMM-3 trial. Elrex fio is approved for patients with at least four prior treatments.
Seeking Alpha · 2h ago
Is It Too Late to Buy Pfizer Stock?
Pfizer's critics say it's too late to buy shares of Pfizer stock. The company's top line and earnings are trending downward. But Pfizer has big plans for the future and is on track to meet them. Pfizer is one of the world's biggest pharmaceutical companies and has a strong pipeline.
The Motley Fool · 4h ago
Pfizer's ELREXFIO Shows Median Overall Survival Of More Than Two Years In Phase 2 MagnetisMM-3 Study
Patients in MagnetisMM-3 demonstrated a median overall survival (OS) of 24.6 months, with median progression-free survival (PFS) of 17.2 months. The study is a Phase 2 study of ELREXFIO in patients with relapsed or refractory multiple myeloma.
Benzinga · 7h ago
ELREXFIO™ Shows Median Overall Survival of More Than Two Years in People with Relapsed or Refractory Multiple Myeloma
Pfizer announces overall survival results from the Phase 2 MagnetisMM-3 study of ELREXFIO in patients with relapsed or refractory multiple myeloma. The study demonstrated a median OS of 24.6 months in patients in the pivotal single arm trial. ELREFIO received accelerated approval in August 2023 from the U.S. For the treatment of RRMM.
Barchart · 13h ago
More
About PFE
Pfizer Inc. is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment is engaged in the science-based biopharmaceutical business. Its Biopharma segment includes the Pfizer Oncology Division, the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its Oncology products include Ibrance, Xtandi, Inlyta, Bosulif, Lorbrena, Braftovi, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio and Tivdak. Its primary care products include Eliquis, Nurtec ODT/Vydura, Comirnaty, the Prevnar family, Abrysvo, FSME/IMMUN-TicoVac, Paxlovid and Lucira by Pfizer. Its specialty care products include Xeljanz, Enbrel (outside the U.S. and Canada), Inflectra, Cibinqo, Litfulo, Vyndaqel family, Genotropin, Sulperazon, Zavicefta, Medrol and Panzyga.

Webull offers Pfizer Inc stock information, including NYSE: PFE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PFE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PFE stock methods without spending real money on the virtual paper trading platform.